Gilead Sciences

Congo Ebola Outbreak: Merck Ervebo Vaccine, Gilead Remdesivir Eyed for Wider Use

Merck & Co.’s Ebola vaccine and an antiviral drug from Gilead Sciences Inc. are set for wider use in eastern Democratic Republic of Congo to blunt the fastest-growing Ebola outbreak on record.

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend. The post Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat appeared first on Investor's Business Daily .